Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

B&M profits above guidance mid-point after solid Q4

(Sharecast News) - Discount retailer B&M has said that adjusted operating profits should be above the mid-point of its guidance range for the year ended 29 March on the back of productivity gains and a pick-up in underlying sales growth in the fourth quarter. Guidance for adjusted EBITDA was cut in February to £605m-625m, down from an earlier forecast of £620m-650m.

Full-year group revenues totalled £5.6bn, up 3.7% on the year before as the impact of a 5% increase in store numbers and positive like-for-like sales in France (+2.6%) offset falling LFL sales in B&M UK (-3.1%) and the Heron Foods division.

At B&M UK, which accounts for around four fifths of group sales, headline sales increased by 5.4% in the fourth quarter, picking up from the 2.8% growth seen in the third.

Sales still fell on an underlying basis, as positive general merchandise sales - helped by the garden, toys, paint and stationery categories - were outweighed by a weaker performance in FMCG, but the LFL decline eased to -1.8% from -2.8%.

Operating costs at B&M UK rose by 6% over the year, as new store growth, greater volumes and higher wage rates "have been partly mitigated by productivity gains", the company said.

B&M, which announced in February that chief executive Alex Russo would be stepping down at the end of this month, said it is making progress on its CEO succession plans and will make an announcement "in the coming weeks".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.